Charles K. Gayer
CEO, President & DirectorMr. Charles K. Gayer, also known as Charlie, is President at BioCryst Pharmaceuticals, Inc. since August 1, 2025 and serves as its Chief Executive Officer & Director since January 01, 2026. He served as the Senior Vice President at BioCryst Pharmaceuticals, Inc. since January 2020 until August 1, 2025 and serves\d as its Chief Commercial Officer since January 2020 until January 01, 2026. Mr. Gayer joined BioCryst in August 2015 as vice president of global strategic marketing. Since July 2019 he has served as interim chief commercial officer, playing a key role in defining the strategy and building the commercial operations, to support the launch of berotralstat, BioCryst’s oral kallikrein inhibitor for hereditary angioedema (HAE). Prior to joining BioCryst, Mr. Gayer held several U.S. and global commercial leadership roles in competitive rare disease categories at Talecris Biotherapeutics, Inc., a biopharmaceutical company that was acquired in 2011 by Grifols, S.A., a multinational pharmaceutical and chemical manufacturer. He was employed at Grifols and Talecris Biotherapeutics from 2007 through 2015. At Talecris, he led U.S. alpha-1 antitrypsin deficiency marketing and later European sales and marketing. At Grifols, he led the U.S. marketing team for the combined immune globulin portfolio of the two companies. Prior to joining Talecris, he spent six years at GlaxoSmithKline in a range of marketing and sales roles. Mr. Gayer began his career as a strategic consultant for biopharmaceutical companies and also spent three years as a business analyst at rare disease pioneer Genzyme Corporation. He received his B.A. in politics from Princeton University and his M.B.A. from the Fuqua School of Business of Duke University.
Positions
- Company NameBioCryst Pharmaceuticals, Inc.Stock CodeBCRXPositionCEO, President & DirectorColleagues
- VJVincent J. MilanoIndependent Chairman
- BGBabar GhiasCFO & Head of Corporate Development
- APAlane P. BarnesSenior VP, Chief Legal Officer & Corporate Secretary
- JRJohn RueschChief Technical Operations Officer
- DWDavid W. JenkinsChief Scientific Officer
- AGAlan G. LevinIndependent Director
- SKSteven K. GalsonIndependent Director
- AMA. Machelle SandersIndependent Director
